What is new at EpiPharm
EpiPharm AG is proud to announce the online publication in the BJD of the exploratory study on the topical use of artemether in patients with seborrheic keratosis. Data demonstrate clinically relevant improvement with long lasting effect in 2/3 of lesions treated. (https://doi.org/10.1111/bjd.16930)
EpiPharm AG announces the issuance of the European patent for use of artemisinins for the treatment of seborrheic keratosis.
EpiPharm is pleased to announce the selection of a faster acting and more potent member of the artemisinin class as lead compound and progression to phase 2.
EpiPharm AG announces the issuance of the US patent for use of artemisinins for the treatment of seborrheic keratosis.
November 5-7, 2018:
Meet us at Bio-Europe in Copenhagen, Denmark.
EpiPharm will be represented by Mark Palmer, Director, Triad Securities.
Please send your meeting requests for partnering to: firstname.lastname@example.org